Zhang Yinghong, Hu Yu, Guo Tao, Wei Wenning, Zhang Xiaoping
The Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
J Huazhong Univ Sci Technolog Med Sci. 2008 Apr;28(2):140-3. doi: 10.1007/s11596-008-0206-6. Epub 2008 May 15.
To clarify the role of TAFI in hypertensive disorders in pregnancy, 22 subjects, including 10 with pre-eclampsia (PE) and 12 with gestational hypertension were examined for the levels of TAFI and thrombin-antithrombin (TAT) complex. Thirty normal pregnant women served as controls. ELISA was employed for the detection. The results showed that the TAFI antigen levels in normal pregnancy group, gestational hypertension group and PE group were (85.35+/-24.69)%, (99.65+/-18.27)%, (110.12+/-23.36)%; (97.06+/-21.40)%, (114.08+/-27.76)%, (125.49+/-24.70)%; (106.6+/-19.21)%, (129.2+/-25.07)%, (139.1+/-30.12)%, in the 1st, 2nd and 3rd trimester respectively. No significant differences were found between the normal pregnancy group and gestational hypertension group but significant difference existed between normal pregnancy group and PE group in each trimester (P<0.05). TAT complexes were significantly higher in patients with PE than that in controls (P<0.05), but no correlation was found between TAT and TAFI. It is concluded that TAFI may contributed to the impairment of fibrinolysis in the patients with PE and may serves as a sensitive indicator for PE, but it may not help in the diagnosis of the gestational hypertension.
为阐明凝血酶激活的纤溶抑制物（TAFI）在妊娠期高血压疾病中的作用，对22名受试者进行了TAFI和凝血酶 - 抗凝血酶（TAT）复合物水平检测，其中包括10例先兆子痫（PE）患者和12例妊娠期高血压患者。30名正常孕妇作为对照。采用酶联免疫吸附测定（ELISA）进行检测。结果显示，正常妊娠组、妊娠期高血压组和PE组的TAFI抗原水平在妊娠第1、2、3期分别为（85.35±24.69）%、（99.65±18.27）%、（110.12±23.36）%；（97.06±21.40）%、（114.08±27.76）%、（125.49±24.70）%；（106.6±19.21）%、（129.2±25.07）%、（139.1±30.12）%。正常妊娠组和妊娠期高血压组之间未发现显著差异，但在各孕周正常妊娠组与PE组之间存在显著差异（P<0.05）。PE患者的TAT复合物明显高于对照组（P<0.05），但未发现TAT与TAFI之间存在相关性。结论是，TAFI可能导致PE患者纤溶功能受损，可作为PE的敏感指标，但对妊娠期高血压的诊断可能无帮助。
